



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Keith D. ALLEN

Application No.: 09/903,395

Filed: July 10, 2001

For: Transgenic Mice Containing
Melanocortin-3 Receptor Gene
Disruptions

Examiner: Michael C. Wilson

Art Unit: 1632

Atty. Docket No.: R-653

RECEIVED

DEC 13 2002

TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the examination of the above-referenced application and in response to the U.S. Patent Office Notice mailed November 15, 2002, entry of the following amendment is respectfully requested:

In the Specification

Please replace the paragraph on page 9, lines 24-27, with the following paragraph:

--Figure 2 (Panels A and B) shows design of the targeting construct used to disrupt melanocortin-3 receptor genes. Figure 2 (Panel A), which illustrates the target sequence (SEQ ID NO:1) for the targeting construct, shows the location and extent of the disrupted portion of the melanocortin-3 receptor genes, as well as the nucleotide sequences flanking the Neo' insert in the targeting construct. Figure 2 (Panel B) shows the sequences identified as SEQ ID NO:3 and SEQ ID NO:4, which were used as the targeting arms (homologous sequences) in the melanocortin-3 receptor targeting construct.--

In the Drawings

Please replace Figure 2A in the application with the enclosed new Figure 2A. A marked-up copy of Figure 2A is also enclosed, with corrections indicated in red.